EUCTR2012-005524-15-ES进行中（未招募）不适用
A 12-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Signed and dated written informed consent obtained in accordance with local regulations.
- •- Completes the Week 12 visit in study AG201 while taking their assigned does of study drug.
- •- Has no new medical condtraindication to continue participation in the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 300
排除标准
- •-Is currently using any other investigational or experimental drugs or devices.
- •- Has significant worsening of medical conditions or dementia such that it may preclude completion of this safety extension study.
研究者
相似试验
进行中（未招募）
1 期
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease.EUCTR2012-005524-15-GBElan Pharma International Ltd400
已完成
不适用
Safety evaluation of long-term NMN in healthy peopleJPRN-jRCTs031180242Itoh Hiroshi30
进行中（未招募）
1 期
Safety of continued use of oral docetaxel in patients with advanced solid types of cancerEUCTR2017-000347-41-NLModra Pharmaceuticals BV45
已完成
2 期
Dose-escalating, phase 2 study of oral lisdexamfetamine in adults with methamphetamine dependenceACTRN12615000391572St. Vincent's Hospital, Sydney20
尚未招募
不适用
Effect of 4 weeks of oral D. piger on safety, pharmacokinetics and ethanol metabolism in overweight individuals (2023)Metabolic dysfunction associated steatotic liver disease (MASLD)NAFLD10019654NL-OMON56584Amsterdam UMC20